Full Press Release Details
HOUSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will participate in the following upcoming investor conferences:
JonesTrading C-Suite Fireside Chat SeriesDate: Wednesday, February 19, 2026Time: 11:00 AM ESTRegistration Linkhere
Oppenheimer 36thAnnual Healthcare Life Sciences ConferenceFormat: Corporate presentationDate: Wednesday, February 25, 2026Time: 10:40 AM ESTLocation: Virtual
TD Cowen 46thAnnual Health Care ConferenceFormat: Corporate presentationDate: Tuesday, March 3, 2026Time: 1:50 PM ESTLocation: Boston, MA
Barclays 28thAnnual Global Healthcare ConferenceFormat: Fireside chatDate: Tuesday, March 10, 2026Time: 2:00 PM ESTLocation: Miami Beach, FL
The webcast of the JonesTrading fireside chat and Oppenheimer presentation will be accessible on theTvardi Investors’ website. A replay of the webcasts will be available for approximately 90 days following the conference.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visittvarditherapeutics.comor follow us on LinkedIn and X (Twitter).
Contacts:
For Tvardi:Tvardi Investor Relationsir@tvardi.com
PJ KelleherLifeSci Advisors617-430-7579pkelleher@lifesciadvisors.com